Updates on the Management of Thyroid Cancer.
Publication Title
Hormone and metabolic research. Hormon- und Stoffwechselforschung. Hormones et metabolisme
Document Type
Article
Publication Date
2-10-2020
Abstract
The diagnostic modalities, stratification tools, and treatment options for patients with thyroid cancer have rapidly evolved since the development of the American Thyroid Association (ATA) guidelines in 2015. This review compiles newer concepts in diagnosis, stratification tools and treatment options for patients with differentiated thyroid cancer (DTC), medullary thyroid carcinoma (MTC) and anaplastic thyroid cancer (ATC). Newer developments apply precision medicine in thyroid cancer patients to avoid over-treatment in low risk disease and under-treatment in high risk disease. Among novel patient-tailored therapies are selective RET inhibitors that have shown efficacy in the treatment of MTC with limited systemic toxicity compared with non-specific tyrosine kinase inhibitors. The combination of BRAF and MEK inhibitors have revolutionized management of
Clinical Institute
Cancer
Specialty/Research Institute
Oncology
Specialty/Research Institute
Endocrinology
